Trachoma Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Market is segmented by Route of Administration (Oral and Topical), Drug Class (Macrolides, Tetracycline, Ophthalmic anti-infective, and Sulfonamides), and Geography.

Market Snapshot

Trachoma treatment market
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: Middle-East and Africa
CAGR: 5.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The trachoma treatment market is expected to register a CAGR of 5.5% during the forecast period. This is attributed to the increasing prevalence of trachoma due to the rising air pollution, and the lack of maintenance of personal hygiene by majority of people in underdeveloped countries. 

  • Trachoma is an infectious eye disease, which is caused by bacterium chlamydia trachomatis, and as per the World Health Organization (WHO), it is the leading cause of blindness and one of 20 neglected tropical diseases that affects one billion of the world’s poorest people. 
  • Moreover, poor sanitation, such as sharing the used towels and clothes and unhygienic water and food consumption, may propel the studied market's growth in underdeveloped countries. In addition, as per the World Health Organization (2018), globally, an estimated 89.1 million people had been treated with antibiotics for eliminating trachoma, which further boost the revenue growth of the market studied.

Scope of the Report

Trachoma is a bacterial infection and the leading cause of preventable blindness. Treatment includes antibiotics and surgeries. The trachoma treatment market is segmented by route of administration, drug class, and geography.

By Route of Administration
Oral
Topical
By Drug Class
Macrolides
Tetracycline
Ophthalmic anti-infective
Sulfonamides
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Oral Route of Administration is Dominating the Market

The oral route of administration segment is expected to hold a largest market share, owing to easy mode of administration with most favored, ease of production, cost effectiveness, flexibility in design of dosage forms, and least sterility constraints. As antibiotics are the first line of therapy for the targeted patient pool, it may boost the revenue growth of the segment. Antibiotics, such as azithromycin and tetracycline, are the most commonly used for the treatment of trachoma.

key trends trachoma 1.png

Middle East & Africa is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The Middle East & Africa is expected to hold a significant market share in the global trachoma treatment market, as it is the most affected region with trachoma cases. As per the World Health Organization (WHO), in 2016, an estimated 247,000 people being treated with surgical treatment for trichiasis, and 83 million people were treated with antibiotic therapy. In addition, 142 million people live in trachoma endemic areas and are at risk of trachoma blindness, which further propels the revenue growth of this region.

geography trachoma.png

Competitive Landscape

The market studied is moderately competitive, and there are several international as well as local companies. Some of the companies that are currently dominating the market are Allergan, Apotex, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Sandoz Inc. (Novartis AG), Arbor Pharmaceuticals Inc., Fresenius Kabi AG, Merck & Co. Inc., and AbbVie Inc., among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence and Prevalence of Trachoma

      2. 4.2.2 Favourable Government Initiative

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness

      2. 4.3.2 Side Effects

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Route of Administration

      1. 5.1.1 Oral

      2. 5.1.2 Topical

    2. 5.2 By Drug Class

      1. 5.2.1 Macrolides

      2. 5.2.2 Tetracycline

      3. 5.2.3 Ophthalmic anti-infective

      4. 5.2.4 Sulfonamides

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Allergan

      2. 6.1.2 Apotex

      3. 6.1.3 Pfizer Inc.

      4. 6.1.4 Teva Pharmaceutical Industries Ltd

      5. 6.1.5 Sandoz Inc. (Novartis AG)

      6. 6.1.6 Arbor Pharmaceuticals Inc.

      7. 6.1.7 Fresenius Kabi AG

      8. 6.1.8 Merck & Co. Inc.

      9. 6.1.9 AbbVie Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Trachoma Treatment Market market is studied from 2018 - 2026.

The Trachoma Treatment Market is growing at a CAGR of 5.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

Middle-East and Africa holds highest share in 2021.

Allergan, Pfizer Inc, Apotex, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG are the major companies operating in Trachoma Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!